Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
US doctors seem to be very willing to start drugs earlier in disease, while their EU colleagues are slower and more conservative. Recent examples: the ever-wider indication for statins, the disproportionate uptake of drugs for attention-deficit / hyperactivity and opioids Continue reading HIV Therapy Guidance Recommendations Diverge, Show US Bias
It was clear from the outset that the new roster of HCV drugs would change the playing field. Gilead’s NS5B polymerase inhibitor sofosbuvir and J&J’s NS3/4A protease inhibitor simeprevir have already revolutionized the treatment paradigm, pushing telaprevir and boceprevir, the Continue reading So Many HCV “Guidelines”: Can’t We Wait Till the Dust Has Settled?